The Israeli Tax Authority recently published a tax decision (the “Decision”), which concerns the issue of liability for value added

Client Update | Value Added Tax | Tax Liability in a Transaction for the Sale of Shares on Credit

On March 28, 2019, Israel and Australia signed their first ever tax treaty (the “Treaty”). The purpose of the Treaty

Client Update | A New Tax Treaty between Israel and Australia

New Israeli Income Tax Regulations, which were officially published on 6 February 2019 (the “Regulations”), implement the Common Standard on Reporting

Client Update | Israel Approves CRS Regulations on the Exchange of Financial Information

The Tel Aviv District Court recently delivered a decision in a tax appeal of Broadcom (Tax Appeal 17419-02-18), finding that

Client Update | Israeli District Court: In an IP/FAR Tax Case the Burden of Proof is on the Taxpayer

On January 17, 2019, Israel and the UK signed a significant Amending Protocol to the 1962 Income Tax Treaty between

Client Update | Revisions to Tax Treaty between Israel and the United Kingdom

Herzog Fox & Neeman Managing Partner, Meir Linzen, together with Partners, Guy Katz and Yuval Navot, authored Chambers & Partners

Chambers & Partners | Corporate Tax 2019

This is an important update for multinational groups with business activities or affiliates in Israel, and is particularly relevant for

Client Update | Change of a Business Model in Multinational Groups

Recently Israel informed the OECD that it has ratified the Multilateral Convention to Implement Tax Treaty Related measures to prevent

Tax Client Update | Israel Ratifies the MLI

Herzog Fox & Neeman’s tax partners, Meir Linzen and Guy Katz, co-authored the Israel Law and Practice chapter, providing easily

Chambers Tax Guide 2018 | Law & Practice Chapter by Meir Linzen and Guy Katz

Teva Pharmaceuticals Industries Limited announced on March 7th 2018, the pricing of an offering of $4.5 Billion senior notes. Herzog

Herzog Fox & Neeman Acted as Israeli Counsel for a Consortium of Banks in a 4.5 Billion Debt Offering by Teva Pharmaceutical Industries Ltd.